Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278902 · ClinicalTrials.gov registry record · Phase 1
A Study of ARRY-334543 in Patients With Advanced Cancer
A Phase 1 study of Advanced Cancer, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 5
- Study locations
NCT00278902: Completed Phase 1 study of Advanced Cancer, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
NCT00278902 is a Phase 1 study of Advanced Cancer that has completed, run by Array Biopharma, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 96 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (61% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00278902, a Phase 1 study of Advanced Cancer, has completed, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-334543. This study has 2 parts. In the first part, patients will receive increasing doses of study drug (2 dosing schedules will be evaluated) in order to achieve the highest dose possible that will not cause unacceptable side effects. Approximately 70 patients from the US and Canada will be enrolled in Part 1 (Completed). In the second part of the study, patients will receive the best dose(s) and schedule(s) of study drug determined from the first part of the study and will be followed to see what side effects the study drug causes and what effectiveness it has, if any, in treating the cancer. Approximately 40 patients from the US and Canada will be enrolled in Part 2 (Completed).
Conditions Studied
Interventions
- DRUG ARRY-334543, EGFR/ErbB2 inhibitor; oral
Study Locations (5)
Tennessee
- Sarah Cannon Research Center - Nashville
- Vanderbilt University Medical Center - Nashville
British Columbia
- British Columbia Cancer Agency- Centre for the Southern Interior - Kelowna
- British Columbia Cancer Agency - Vancouver
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
What the finished NCT00278902 record still lists
NCT00278902 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which ARRY-334543, EGFR/ErbB2 inhibitor; oral is the first listed.
NCT00278902 lists 5 locations in 3 states (Tennessee, British Columbia, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00278902 about?
NCT00278902 is a clinical study titled "A Study of ARRY-334543 in Patients With Advanced Cancer". This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-334543. This study has 2 parts. In the first part, patients will receive increasing doses of study drug (2 dosing schedules will be evaluated) in order to achieve the highest dose p...
What is the current status of trial NCT00278902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2006-01. Estimated completion is 2009-06.
What conditions does trial NCT00278902 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00278902?
The interventions under investigation include: ARRY-334543, EGFR/ErbB2 inhibitor; oral (DRUG).
Who is sponsoring clinical trial NCT00278902?
This trial is sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00278902 being conducted?
This trial has 5 study locations across Pennsylvania, Tennessee, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00278902's enrollment target sits among peer trials
96 60th of 122 higher than 63 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia